Publications

  1. Zhang T, Ambrodji A, Huang H, Bouchonville KJ, Etheridge AS, Schmidt RE, Bembenek BM, Temesgen ZB, Wang Z, Innocenti F, Stroka D, Diasio RB, Largiader CR, Offer SM. Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD). Elife. 2024 Apr 30; 13
    View PubMed
  2. Le Teuff G, Cozic N, Boyer JC, Boige V, Diasio RB, Taieb J, Meulendijks D, Palles C, Schwab M, Deenen M, Largiader CR, Marinaki A, Jennings BA, Wettergren Y, Di Paolo A, Gross E, Budai B, Ackland SP, van Kuilenburg ABP, McLeod HL, Milano G, Thomas F, Loriot MA, Kerr D, Schellens JHM, Laurent-Puig P, Shi Q, Pignon JP, Etienne-Grimaldi MC, FUSAFE collaborative group. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. Br J Cancer. 2024 Mar; 130 (5):808-818 Epub 2024 Jan 15
    View PubMed
  3. Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May 20; 41 (15):2701-2705 Epub 2023 Feb 23
    View PubMed
  4. Lumish M, Thackray J, Do RKG, Caudle KE, Amstutz U, Schwab M, Diasio RB, Jarnagin WR, Cercek A. Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine. JCO Precis Oncol. 2023 Feb; 7:e2200442
    View PubMed
  5. Diasio RB, Offer SM. Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy. Cancers (Basel). 2022 Jun 30; 14 (13) Epub 2022 June 30
    View PubMed
  6. Diasio RB, Innocenti F, Offer SM. Pharmacogenomic-Guided Therapy in Colorectal Cancer. Clin Pharmacol Ther. 2021 Sep; 110 (3):616-625 Epub 2021 July 10
    View PubMed
  7. Hamzic S, Scharer D, Offer SM, Meulendijks D, Nakas C, Diasio RB, Fontana S, Wehrli M, Schurch S, Amstutz U, Largiader CR. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. Br J Clin Pharmacol. 2021 Aug; 87 (8):3234-3243 Epub 2021 Mar 30
    View PubMed
  8. ReFaey K, Tripathi S, Grewal SS, Bhargav AG, Quinones DJ, Chaichana KL, Antwi SO, Cooper LT, Meyer FB, Dronca RS, Diasio RB, Quinones-Hinojosa A. Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun; 5 (3):645-653 Epub 2021 June 08
    View PubMed
  9. Wang Z, Wu R, Nie Q, Bouchonville KJ, Diasio RB, Offer SM. Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance. J Natl Cancer Cent. 2021 Mar; 1 (1):15-22 Epub 2021 Jan 16
    View PubMed
  10. Schaerer D, Froehlich TK, Hamzic S, Offer SM, Diasio RB, Joerger M, Amstutz U, Largiader CR. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. J Pers Med. 2020 Oct 19; 10 (4)
    View PubMed
  11. Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB 3rd. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Oncologist. 2020 May; 25 (5):e798-e807 Epub 2019 Dec 18
    View PubMed
  12. Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M, Offer SM, Diasio RB, Skaar TC. Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing. JCO Precis Oncol. 2020; 4 Epub 2020 June 12
    View PubMed
  13. Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddiqui NS, Godara A, Diasio RB. Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Arch Pharmacol Ther. 2020; 2 (1):6-8
    View PubMed
  14. Dai J, Liu M, Yang Y, Li Q, Song N, Rocco G, Sihoe ADL, Gonzalez-Rivas D, Suen HC, He W, Duan L, Fan J, Zhao D, Wang H, Zhu Y, Chen C, Diasio RB, Jiang G, Yang P, Zhang P. Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer. J Thorac Oncol. 2019 Jul; 14 (7):1277-1285 Epub 2019 Apr 19
    View PubMed
  15. Li Q, Zhang P, Wang Y, Liu D, Luo L, Diasio RB, Yang P, Jiang G. T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0-1M0 non-small-cell lung cancer†. Eur J Cardiothorac Surg. 2019 Apr 01; 55(4):682-690.
    View PubMed
  16. Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther. 2019 Mar; 105 (3):598-613 Epub 2018 Sept 11
    View PubMed
  17. Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, Diasio RB. Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther. 2018 Oct; 104 (4):709-718 Epub 2018 Feb 02
    View PubMed
  18. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018 Feb; 103 (2):210-216 Epub 2017 Nov 20
    View PubMed
  19. Shrestha S, Tapper EE, Trogstad-Isaacson CS, Hobday TJ, Offer SM, Diasio RB. Dose modification for safe treatment of a compound complex heterozygous DPYD variant carrier with 5-fluorouracil. JCO Precis Oncol. 2018; 2 Epub 2018 Oct 03
    View PubMed
  20. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 Nov; 18 (11):e653-e706 Epub 2017 Oct 31
    View PubMed
  21. Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB. Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity. Clin Pharmacol Ther. 2017 Oct; 102 (4):662-670 Epub 2017 May 26
    View PubMed
  22. Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB. Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther. 2017 Mar; 101 (3):382-390 Epub 2016 Nov 26
    View PubMed
  23. Flores JP, Diasio RB, Saif MW. Drug metabolism and pancreatic cancer. Ann Gastroenterol. 2017; 30 (1):54-61 Epub 2016 July 21
    View PubMed
  24. Wu R, Nie Q, Tapper EE, Jerde CR, Dunlap GS, Shrestha S, Elraiyah TA, Offer SM, Diasio RB. Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter. Cancer Res. 2016 Nov 1; 76 (21):6362-6373 Epub 2016 Aug 30
    View PubMed
  25. Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol. 2016 Oct-Dec; 29 (4):551-556 Epub 2016 June 10
    View PubMed
  26. Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, Alvarnas JC, Levine HA, Fong Y, Weisenburger DD, Fitzgerald CL, Egan M, Stranford S, Carlson RW, Benz EJ Jr. Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers. J Natl Compr Canc Netw. 2016 Jul; 14 (7):837-47
    View PubMed
  27. Diasio RB. Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil. Clin Adv Hematol Oncol. 2016 Jul; 14: (7)510-2.
    View PubMed
  28. Saif MW, Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Cancer Chemother Pharmacol. 2016 Jul; 78 (1):151-6 Epub 2016 June 08
    View PubMed
  29. Offer SM, Diasio RB. Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial. JAMA Oncol. 2016 May 1; 2 (5):662-663
    View PubMed
  30. Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JHM, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016 Mar 16; 7:10880
    View PubMed
  31. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26 (3):133-7
    View PubMed
  32. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun. 2015 Jul 22; 6:7539 Epub 2015 July 22
    View PubMed
  33. Jang JS, Lee A, Li J, Liyanage H, Yang Y, Guo L, Asmann YW, Li PW, Erickson-Johnson M, Sakai Y, Sun Z, Jeon HS, Hwang H, Bungum AO, Edell ES, Simon VA, Kopp KJ, Eckloff B, Oliveira AM, Wieben E, Aubry MC, Yi E, Wigle D, Diasio RB, Yang P, Jen J. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers. Sci Rep. 2015 May 18; 5:9755
    View PubMed
  34. Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiader CR. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res. 2015 May 1; 21 (9):2038-44 Epub 2015 Feb 05
    View PubMed
  35. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Nov 07
    View PubMed
  36. Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 2014 Jun 15; 20 (12):3319-27 Epub 2014 Apr 11
    View PubMed
  37. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014 May 1; 74 (9):2545-54 Epub 2014 Mar 19
    View PubMed
  38. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther. 2014 Mar; 13 (3):742-51 Epub 2014 Jan 08
    View PubMed
  39. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014 Feb 1; 120 (3):415-24 Epub 2013 Oct 21
    View PubMed
  40. Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin Proc. 2014 Jan; 89 (1):131-136
    View PubMed
  41. Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, Dogan A, Diasio RB, Gupta M. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy. Leukemia. 2014 Jan; 28 (1):147-54 Epub 2013 Aug 27
    View PubMed
  42. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013 Dec; 94: (6)640-5.
    View PubMed
  43. Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013 Jul; 94 (1):158-66 Epub 2013 Apr 03
    View PubMed
  44. Zhang Y, Kent JW 2nd, Lee A, Cerjak D, Ali O, Diasio R, Olivier M, Blangero J, Carless MA, Kissebah AH. Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population. BMC Med Genomics. 2013 Mar 19; 6:9.
    View PubMed
  45. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013 Mar 15; 73 (6):1958-68 Epub 2013 Jan 17
    View PubMed
  46. Greenberg AJ, Lee AM, Serie DJ, McDonnell SK, Cerhan JR, Liebow M, Larson DR, Colby CL, Norman AD, Kyle RA, Kumar S, Rajkumar SV, Diasio RB, Slager SL, Vachon CM. Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. Leukemia. 2013 Feb; 27: (2)515-6.
    View PubMed
  47. Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2013 Jan; 79: (1)27-32.
    View PubMed
  48. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomaki K, Amiano P, Apicella C, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Muller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM, Australian Breast Cancer Tissue Bank Investigators//Familial Breast Cancer Study//GENICA Consortium. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15; 21 (24):5373-84 Epub 2012 Sept 13
    View PubMed
  49. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012 Nov 10; 30 (32):3932-8 Epub 2012 Sept 17
    View PubMed
  50. Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, Brent CR, Kruse JJ, Ezzell GA, Herman MG, Gunderson LL, Erlichman C, Diasio RB. The clinical case for proton beam therapy. Radiat Oncol. 2012 Oct 22; 7:174
    View PubMed
  51. Stevens KN, Lindstrom S, Scott CG, Thompson D, Sellers TA, Wang X, Wang A, Atkinson E, Rider DN, Eckel-Passow JE, Varghese JS, Audley T, Brown J, Leyland J, Luben RN, Warren RM, Loos RJ, Wareham NJ, Li J, Hall P, Liu J, Eriksson L, Czene K, Olson JE, Pankratz VS, Fredericksen Z, Diasio RB, Lee AM, Heit JA, DeAndrade M, Goode EL, Vierkant RA, Cunningham JM, Armasu SM, Weinshilboum R, Fridley BL, Batzler A, Ingle JN, Boyd NF, Paterson AD, Rommens J, Martin LJ, Hopper JL, Southey MC, Stone J, Apicella C, Kraft P, Hankinson SE, Hazra A, Hunter DJ, Easton DF, Couch FJ, Tamimi RM, Vachon CM. Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet. 2012 Jul 15; 21 (14):3299-305 Epub 2012 Apr 24
    View PubMed
  52. Taga M, Mechanic LE, Hagiwara N, Vahakangas KH, Bennett WP, Alavanja MC, Welsh JA, Khan MA, Lee A, Diasio R, Edell E, Bungum A, Jang JS, Yang P, Jen J, Harris CC. EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. Cancer Epidemiol Biomarkers Prev. 2012 Jun; 21: (6)988-92.
    View PubMed
  53. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18 (2):546-54
    View PubMed
  54. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29 (34):4561-7 Epub 2011 Oct 11
    View PubMed
  55. Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, Tollenaar RA, Van't Veer LJ, Fasching PA, Beckmann MW, Ekici AB, Strick R, Peto J, dos Santos Silva I, Fletcher O, Johnson N, Sawyer E, Johnson N, Tomlinson I, Kerin M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Bojesen S, Flyger H, Nordestgaard BG, Benitez J, Milne RL, Ignacio Arias J, Zamora MP, Brenner H, Muller H, Arndt V, Rahman N, Turnbull C, Seal S, Renwick A, Brauch H, Justenhoven C, Bruning T, Chang-Claude J, Hein R, Wang-Gohrke S, Dork T, Schurmann P, Bremer M, Hillemanns P, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Bogdanova N, Antonenkova N, Rogov YI, Karstens JH, Bermisheva M, Prokofieva D, Gantcev SH, Khusnutdinova E, Lindblom A, Margolin S, Chenevix-Trench G, Beesley J, Chen X, Mannermaa A, Kosma VM, Soini Y, Kataja V, Lambrechts D, Yesilyurt BT, Chrisiaens MR, Peeters S, Radice P, Peterlongo P, Manoukian S, Barile M, Couch F, Lee AM, Diasio R, Wang X, Giles GG, Severi G, Baglietto L, Maclean C, Offit K, Robson M, Joseph V, Gaudet M, John EM, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight JA, Mulligan AM, O'Malley FP, Brinton LA, Sherman ME, Lissowska J, Chanock SJ, Hooning M, Martens JW, van den Ouweland AM, Collee JM, Hall P, Czene K, Cox A, Brock IW, Reed MW, Cross SS, Pharoah P, Dunning AM, Kang D, Yoo KY, Noh DY, Ahn SH, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Shen CY, Ding SL, Hsu HM, Yu JC, Anton-Culver H, Ziogas A, Ashworth A, Swerdlow A, Jones M, Orr N, Trentham-Dietz A, Egan K, Newcomb P, Titus-Ernstoff L, Easton D, Spurdle AB, GENICA Network//kConFab AOCS Management Group. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011 Dec 1; 20 (23):4693-706 Epub 2011 Aug 18
    View PubMed
  56. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, Dimopoulos AM, Driver WR, Dunnebier T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Forsti A, Fountzilas G, Gerty SM, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Marchand LL, Lesnick T, Liu J, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, Press MF, Pylkas K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rudiger T, Silva S, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Van Den Berg D, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ, Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30; 43 (12):1210-4
    View PubMed
  57. Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin AK, Ambrosone C, Winqvist R, Brauch H, Schmidt MK, Cox A, Cross SS, Sawyer E, Hartmann A, Beckmann MW, Schulz-Wendtland R, Ekici AB, Tapper WJ, Gerty SM, Durcan L, Graham N, Hein R, Nickels S, Flesch-Janys D, Heinz J, Sinn HP, Konstantopoulou I, Fostira F, Pectasides D, Dimopoulos AM, Fountzilas G, Clarke CL, Balleine R, Olson JE, Fredericksen Z, Diasio RB, Pathak H, Ross E, Weaver J, Rudiger T, Forsti A, Dunnebier T, Ademuyiwa F, Kulkarni S, Pylkas K, Jukkola-Vuorinen A, Ko YD, Van Limbergen E, Janssen H, Peto J, Fletcher O, Giles GG, Baglietto L, Verhoef S, Tomlinson I, Kosma VM, Beesley J, Greco D, Blomqvist C, Irwanto A, Liu J, Blows FM, Dawson SJ, Margolin S, Mannermaa A, Martin NG, Montgomery GW, Lambrechts D, dos Santos Silva I, Severi G, Hamann U, Pharoah P, Easton DF, Chang-Claude J, Yannoukakos D, Nevanlinna H, Wang X, Couch FJ, GENICA consortium. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res. 2011 Oct 1; 71 (19):6240-9 Epub 2011 Aug 15
    View PubMed
  58. Lee A, Nofziger C, Dossena S, Vanoni S, Diasio R, Paulmichl M. Methylation of the human pendrin promoter. Cell Physiol Biochem. 2011; 28 (3):397-406 Epub 2011 Nov 16
    View PubMed
  59. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010 Dec; 85 (12):1080-9
    View PubMed
  60. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gomez Garcia EB, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Gorski B, Cybulski C, Spurdle AB, Holland H, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rudiger T, Forsti A, Winqvist R, Pylkas K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ, EMBRACE//GEMO Study Collaborators//HEBON//kConFab//SWE-BRCA//MOD SQUAD//GENICA. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010 Oct; 42 (10):885-92 Epub 2010 Sept 19
    View PubMed
  61. Saif MW, Sellers S, Diasio RB, Douillard JY. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs. 2010 Aug; 21: (7)716-23.
    View PubMed
  62. Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res. 2010 Jul 15; 16: (14)3786-94.
    View PubMed
  63. Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. (13)C-5-FU breath test current status and future directions: a comprehensive review. J Breath Res. 2009 Dec; 3(4):047002. Epub 2009 Nov 27.
    View PubMed
  64. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009 Oct 1; 69 (14):1911-34
    View PubMed
  65. Saif MW, Hashmi S, Bell D, Diasio RB. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opin Drug Saf. 2009 Sep; 8(5):507-14.
    View PubMed
  66. Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2008 May; 19: (5)915-9.
    View PubMed
  67. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol. 2008 Jan; 6: (1)41-8.
    View PubMed
  68. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics. 2008 Jan; 18: (1)25-35.
    View PubMed
  69. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics. 2007 Nov; 17: (11)973-87.
    View PubMed
  70. Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Support Cancer Ther. 2007 Sep 1; 4(4):211-8.
    View PubMed
  71. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol. 2007 Sep; 60(4):503-7. Epub 2006 Dec 13.
    View PubMed
  72. Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 2007 Jul-Aug; 13(4):247-56.
    View PubMed
  73. O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, Benson AB 3rd, Rothenberg M, Petrelli N, Lenz HJ, Diasio R, DuBois R, Sargent D, Sloan J, Johnson CD, Comis RL, O'Connell MJ, Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol. 2007 Jun 01; 25: (16)2313-21.
    View PubMed
  74. Zhang X, Soong R, Wang K, Li L, Davie JR, Guarcello V, Diasio RB. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem Cell Biol. 2007 Jun; 85 (3):337-46
    View PubMed
  75. Saif MW, Fekrazad MH, Ledbetter L, Diasio RB. Hypokalemia secondary to capecitabine: a hidden toxicity? Ther Clin Risk Manag. 2007 Mar; 3(1):177-80.
    View PubMed
  76. Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics. 2007 Mar; 8: (3)257-65.
    View PubMed
  77. Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of 4-years. Pak J Med Sci Q. 2007; 23(6):832-9.
    View PubMed
  78. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007 Jan; 12: (1)38-50.
    View PubMed
  79. Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, Wang W, Gillespie GY, Johnson MR. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol. 2006 Dec; 80(3):261-74. Epub 2006 Jun 14.
    View PubMed
  80. Saif MW, Black G, Johnson M, Russo S, Diasio R. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemother Pharmacol. 2006 Dec; 58(6):771-5. Epub 2006 Mar 22.
    View PubMed
  81. Saif MW, Hashmi S, Mattison L, Donovan WB, Diasio RB. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anticancer Drugs. 2006 Oct; 17(9):1095-8.
    View PubMed
  82. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006 Sep 15; 12(18):5491-5.
    View PubMed
  83. Budman DR, Soong R, Calabro A, Tai J, Diasio R. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs. 2006 Sep; 17(8):921-8.
    View PubMed
  84. Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer. 2006 Sep; 6(3):219-23.
    View PubMed
  85. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006 Sep 1; 24(25):4069-77.
    View PubMed
  86. Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol. 2006 Sep; 58(3):396-401. Epub 2006 Jan 19.
    View PubMed
  87. Ezzeldin HH, Diasio RB. Genetic testing in cancer therapeutics. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4137-41.
    View PubMed
  88. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta. 2006 May; 1759(5):247-56. Epub 2006 May 16.
    View PubMed
  89. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn. 2006 Feb; 8(1):76-83.
    View PubMed
  90. Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res. 2006 Jan 15; 12(2):549-55.
    View PubMed
  91. Diasio RB, Fourie J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs. 2006; 66(11):1441-63.
    View PubMed
  92. Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer. 2006 Jan; 5(5):359-62.
    View PubMed
  93. Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer. 2006 Jan; 5(5):354-8.
    View PubMed
  94. Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8773-81.
    View PubMed
  95. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8699-705.
    View PubMed
  96. Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol. 2005 Dec 1; 23(34):8679-87.
    View PubMed
  97. Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 2005 Dec; 6(8):835-47.
    View PubMed
  98. Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005 Aug 15; 11(16):5886-92.
    View PubMed
  99. Saif MW, Diasio RB. Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May; 5(1):27-36.
    View PubMed
  100. Boedefeld WM 2nd, Soong R, Weiss H, Diasio RB, Urist MM, Bland KI, Heslin MJ. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. Mol Carcinog. 2005 May; 43(1):13-7.
    View PubMed
  101. Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 2005 Mar 1; 11(5):1870-6.
    View PubMed
  102. Ozer H, Diasio RB. Perspectives in the treatment of colorectal cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 15):14-8.
    View PubMed
  103. Ezzeldin H, Hoffmayer C, Soong R, Johnson MR, Lee A, Heslin M, Diasio R. Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high-performance liquid chromatography. Anal Biochem. 2004 Nov 15; 334(2):276-83.
    View PubMed
  104. Diasio RB. Selecting regimens in advanced colon cancer. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 3:S-19-24.
    View PubMed
  105. Saif MW, Wood TE, McGee PJ, Diasio RB. Peripheral neuropathy associated with capecitabine. Anticancer Drugs. 2004 Sep; 15(8):767-71.
    View PubMed
  106. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004 Sep; 4(3):181-9.
    View PubMed
  107. Lee A, Ezzeldin H, Fourie J, Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol. 2004 Aug; 2(8):527-32.
    View PubMed
  108. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res. 2004 Apr 15; 10(8):2652-8.
    View PubMed
  109. Diasio RB. Ability of genetic markers to predict quality of life in individual patients. Advances in the Treatment of Gastrointestinal Cancers, American Journal of Oncology Review. 2004; 3(Suppl 9):17-8.
  110. Heslin MJ, Yan J, Weiss H, Shao L, Owens J, Lucas VS, Diasio RB. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):399-404. Epub 2003 Aug 07.
    View PubMed
  111. Diasio RB. Irinotecan in alternative schedules. New Approaches to Stage III and IV Colorectal Cancer. 2003 Sep:22-7.
  112. Diasio R. Alternative schedules with irinotecan. Semin Oncol. 2003 Aug; 30(4 Suppl 12):18-24.
    View PubMed
  113. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res. 2003 Aug 1; 9(8):3021-8.
    View PubMed
  114. Salesiotis A, Soong R, Diasio RB, Frost A, Cullen KJ. Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma. Clin Cancer Res. 2003 Feb; 9(2):580-5.
    View PubMed
  115. Diasio RB. Colorectal cancer treatment update. Vital Signs Monograph. 2003:13-17.
  116. Diasio RB. Pharmacology of novel platinum analogues with activity in colorectal cancer. Advances in Colon Cancer. 2003; 7(2):3-6.
  117. Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct; 1(12):1139-45.
    View PubMed
  118. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2002 Jul; 3(4):485-92.
    View PubMed
  119. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem. 2002 Jul 1; 306(1):63-73.
    View PubMed
  120. Blanquicett C, Johnson MR, Heslin M, Diasio RB. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem. 2002 Apr 15; 303(2):209-14.
    View PubMed
  121. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002 Mar 15; 20: (6)1683-91.
    View PubMed
  122. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res. 2002 Mar; 8(3):768-74.
    View PubMed
  123. Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics. 2002 Mar; 12(2):133-44.
    View PubMed
  124. Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem. 2002 Feb 15; 301(2):189-99.
    View PubMed
  125. Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Invest. 2002; 20(7-8):992-5.
    View PubMed
  126. Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001 Dec; 8(12):966-73.
    View PubMed
  127. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg. 2001 Jun; 233(6):786-92.
    View PubMed
  128. Diasio RB. Current status of oral chemotherapy for colorectal cancer. Oncology (Williston Park). 2001 Mar; 15: (3 Suppl 5)16-20.
    View PubMed
  129. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul. 2001; 41:151-7.
    View PubMed
  130. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park). 2001 Jan; 15: (1 Suppl 2)21-6; discussion 27.
    View PubMed
  131. Shestopal SA, Johnson MR, Diasio RB. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta. 2000 Nov 15; 1494(1-2):162-9.
    View PubMed
  132. Chen L, Smith L, Johnson MR, Wang K, Diasio RB, Smith JB. Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells. J Biol Chem. 2000 Oct 13; 275(41):32227-33.
    View PubMed
  133. Diasio RB. Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Williston Park). 2000 Oct; 14: (10 Suppl 9)19-23.
    View PubMed
  134. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 2000 Sep; 61(3):199-203.
    View PubMed
  135. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000 Apr; 6(4):1322-7.
    View PubMed
  136. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem. 2000 Feb 15; 278(2):175-84.
    View PubMed
  137. Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol. 2000 Feb; 18(4):915-26.
    View PubMed
  138. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999 Aug; 5(8):2006-11.
    View PubMed
  139. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park). 1999 Jul; 13: (7 Suppl 3)17-21.
    View PubMed
  140. Diasio RB. Dihydropyrimidine dehydrogenase and resistance to 5-fluorouracil. Prog Exp Tumor Res. 1999; 36:115-23.
    View PubMed
  141. Diasio RB. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs. 1999; 58 Suppl 3:119-26.
    View PubMed
  142. Diasio RB. Oral administration of fluorouracil: a new approach utilizing modulators of dihydropyrimidine dehydrogenase activity. Cancer Therapeutics. 1999; 2:97-106.
  143. McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, Gonzalez FJ. Nomenclature for human DPYD alleles. Pharmacogenetics. 1998 Dec; 8(6):455-9.
    View PubMed
  144. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston Park). 1998 Oct; 12: (10 Suppl 7)23-7.
    View PubMed
  145. Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol. 1998 Jul; 46(1):1-4.
    View PubMed
  146. Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA 3rd. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
    View PubMed
  147. Diasio RB. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator. Oncology (Williston Park). 1998 Mar; 12: (3 Suppl 4)51-6.
    View PubMed
  148. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1998 Feb; 4(2):325-9.
    View PubMed
  149. Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl. 1997 Aug 29; 696(2):183-91.
    View PubMed
  150. Diasio RB, Zhang R. Pharmacology of therapeutic oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997 Jun; 7(3):239-43.
    View PubMed
  151. Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R, Olsen SJ, Diasio RB. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther. 1997 May; 61(5):563-73.
    View PubMed
  152. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 1997 May 1; 57(9):1660-3.
    View PubMed
  153. Yan J, Lu Z, Walsh GM, Wheeler RH, Diasio RB. High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids. J Chromatogr B Biomed Sci Appl. 1997 Mar 7; 690(1-2):295-303.
    View PubMed
  154. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1997 Mar; 3(3):395-9.
    View PubMed
  155. Morrison GB, Bastian A, Dela Rosa T, Diasio RB, Takimoto CH. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum. 1997 Jan-Feb; 24(1):83-8.
    View PubMed
  156. Johnson MJ, Yan J, Albin N, Diasio RB. Rapid screening for dihydropyrimidine dehydrogenase (DPD) deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Appl. 1997; 696:183-91.
  157. Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR Jr, Grem JL, Allegra CJ, Diasio RB, Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996 Mar; 2(3):477-81.
    View PubMed
  158. Albin N, Johnson MR, Diasio RB. cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. DNA Seq. 1996; 6(4):243-50.
    View PubMed
  159. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther. 1995 Nov; 58(5):512-22.
    View PubMed
  160. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, et al. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol. 1995 Aug 8; 50(4):571-6.
    View PubMed
  161. Zhang R, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Agrawal S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem Pharmacol. 1995 Aug 8; 50(4):545-56.
    View PubMed
  162. Zhang R, Yan J, Shahinian HK, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Diasio RB. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther. 1995 Jul; 58: (1)44-53.
    View PubMed
  163. Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z, Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin Chem. 1995 Jun; 41(6 Pt 1):836-43.
    View PubMed
  164. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol. 1995 Mar 30; 49(7):929-39.
    View PubMed
  165. Diasio RB, Lu Z, Zhang R, Shahinian HS. Fluoropyrimidine catabolism. Cancer Treat Res. 1995; 78:71-93.
    View PubMed
  166. Falany CN, Johnson MR, Barnes S, Diasio RB. Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem. 1994 Jul 29; 269(30):19375-9.
    View PubMed
  167. Diasio RB, Van Kuilenburg AB, Lu Z, Zhang R, Van Lenthe H, Bakker HD, Van Gennip AH. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. Adv Exp Med Biol. 1994; 370:7-10.
    View PubMed
  168. Diasio RB, Lu Z, Zhang R, Cheng X. Genetic polymorphism of dihydropyrimidine dehydrogenase: implications for 5-fluorouracil metabolism and toxicity. Proc Am Assoc Cancer Res. 1994.
  169. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993 Nov 15; 53(22):5433-8.
    View PubMed
  170. Lu ZH, Zhang R, Diasio RB. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties. Biochem Pharmacol. 1993 Sep 1; 46(5):945-52.
    View PubMed
  171. Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol. 1993 Aug; 11(8):1609-17.
    View PubMed
  172. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 1993 Jun 15; 53(12):2816-22.
    View PubMed
  173. Zhang R, Liu T, Soong SJ, Diasio RB. A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil. Biochem Pharmacol. 1993 May 25; 45(10):2063-9.
    View PubMed
  174. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB. Circadian rhythm of rat spleen cytoplasmic thymidine kinase. Biochem Pharmacol. 1993 Mar 9; 45(5):1115-9.
    View PubMed
  175. Sparano JA, Wadler S, Schwartz EL, Diasio R. Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer. Int J Clin Pharmacol Res. 1993; 13(1):1-9.
    View PubMed
  176. Kwakye JB, Barnes S, Diasio RB. Identification of bile acid coenzyme A synthetase in rat kidney. J Lipid Res. 1993 Jan; 34(1):95-9.
    View PubMed
  177. Sparano JA, Wadler S, Schwartz EL, Diasio RB. Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer. 10th Future Trends in Chemotherapy, Bioscience Edisprint, Inc.. 1993; XIII: 1-9.
  178. Lu ZH, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem. 1992 Aug 25; 267(24):17102-9.
    View PubMed
  179. Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi JP. Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. Clin Pharmacol Ther. 1992 Jun; 51(6):668-76.
    View PubMed
  180. Zhang R, Barnes S, Diasio RB. Differential intestinal deconjugation of taurine and glycine bile acid N-acyl amidates in rats. Am J Physiol. 1992 Feb; 262(2 Pt 1):G351-8.
    View PubMed
  181. Zhang RW, Soong SJ, Liu TP, Barnes S, Diasio SB, Diasio RB. Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. Drug Metab Dispos. 1992 Jan-Feb; 20: (1)113-9.
    View PubMed
  182. Kwakye JB, Johnson MR, Barnes S, Grizzle WE, Diasio RB. Identification of bile acid-CoA: amino acid N-acyltransferase in rat kidney. Biochem J. 1991 Dec 15; 280 ( Pt 3):821-4.
    View PubMed
  183. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 1991 Aug 1; 68(3):499-501.
    View PubMed
  184. Daher GC, Naguib FN, el Kouni MH, Zhang RW, Soong SJ, Diasio RB. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochem Pharmacol. 1991 Jun 15; 41(12):1887-93.
    View PubMed
  185. Johnson MR, Barnes S, Kwakye JB, Diasio RB. Purification and characterization of bile acid-CoA:amino acid N-acyltransferase from human liver. J Biol Chem. 1991 Jun 5; 266(16):10227-33.
    View PubMed
  186. Sweeny DJ, Barnes S, Diasio RB. Bile acid conjugation pattern in the isolated perfused rat liver during infusion of an amino acid formulation. JPEN J Parenter Enteral Nutr. 1991 May-Jun; 15(3):303-6.
    View PubMed
  187. Zhang RW, Barnes S, Diasio RB. Disposition and metabolism of 2-fluoro-beta-alanine conjugates of bile acids following secretion into bile. Biochim Biophys Acta. 1991 Apr 15; 1096(3):179-86.
    View PubMed
  188. Kwakye JB, Johnson MR, Barnes S, Diasio RB. A comparative study of bile acid CoA:amino acid:N-acyltransferase (BAT) from four mammalian species. Comp Biochem Physiol B. 1991; 100(1):131-6.
    View PubMed
  189. Coustere C, Mentre F, Sommadossi JP, Diasio RB, Steimer JL. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol. 1991; 28(2):123-9.
    View PubMed
  190. Daher GC, Zhang RW, Soong SJ, Diasio RB. Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy. Drug Metab Dispos. 1991 Jan-Feb; 19(1):285-7.
    View PubMed
  191. Daher GC, Harris BE, Willard EM, Diasio RB. Biochemical basis for circadian-dependent metabolism of fluoropyrimidines. Ann N Y Acad Sci. 1991; 618:350-61.
    View PubMed
  192. Stagg MP, Diasio RB. Novel chemotherapeutic agents in early clinical development. Curr Opin Oncol. 1990 Dec; 2(6):1119-25.
    View PubMed
  193. Johnson MR, Barnes S, Sweeny DJ, Diasio RB. 2-Fluoro-beta-alanine, a previously unrecognized substrate for bile acid coenzyme A:amino acid:N-acyltransferase from human liver. Biochem Pharmacol. 1990 Sep 15; 40(6):1241-6.
    View PubMed
  194. Sweeny DJ, Daher G, Barnes S, Diasio RB. Biological properties of the 2-fluoro-beta-alanine conjugates of cholic acid and chenodeoxycholic acid in the isolated perfused rat liver. Biochim Biophys Acta. 1990 Aug 13; 1054(1):21-5.
    View PubMed
  195. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther. 1990; 48(2):189-222.
    View PubMed
  196. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990 Jan 1; 50(1):197-201.
    View PubMed
  197. Daher GC, Harris BE, Zhang R, Willard EM, Soong SJ, Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dThdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd) following infusion of FUra or FdUrd. Ann Rev of Chronopharm. 1990; 7:227-30.
  198. Harris BE, Song RL, Soong SJ, Diasio RB. Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res. 1989 Dec 1; 49(23):6610-4.
    View PubMed
  199. Johnson MR, Barnes S, Diasio RB. Radioassay of bile acid coenzyme A:glycine/taurine: N-acyltransferase using an n-butanol solvent extraction procedure. Anal Biochem. 1989 Nov 1; 182(2):360-5.
    View PubMed
  200. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989 Apr; 16(4):215-37.
    View PubMed
  201. Harris BE, Song RL, He YJ, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol. 1988 Dec 15; 37(24):4759-62.
    View PubMed
  202. Sweeny DJ, Martin M, Diasio RB. N-chenodeoxycholyl-2-fluoro-beta-alanine: a biliary metabolite of 5-fluorouracil in humans. Drug Metab Dispos. 1988 Nov-Dec; 16(6):892-4.
    View PubMed
  203. Sweeny DJ, Barnes S, Diasio RB. Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver. Cancer Res. 1988 Apr 15; 48(8):2010-4.
    View PubMed
  204. Schuetz JD, Wallace HJ, Diasio RB. DNA repair following incorporation of 5-fluorouracil into DNA of mouse bone marrow cells. Cancer Chemother Pharmacol. 1988; 21(3):208-10.
    View PubMed
  205. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988 Jan; 81(1):47-51.
    View PubMed
  206. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987 Aug; 83(2):236-42.
    View PubMed
  207. Sweeny DJ, Barnes S, Heggie GD, Diasio RB. Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation. Proc Natl Acad Sci U S A. 1987 Aug; 84(15):5439-43.
    View PubMed
  208. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987 Apr 15; 47(8):2203-6.
    View PubMed
  209. Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother. 1986 Jan; 29(1):44-8.
    View PubMed
  210. Schuetz JD, Collins JM, Wallace HJ, Diasio RB. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res. 1986 Jan; 46(1):119-23.
    View PubMed
  211. Schuetz JD, Diasio RB. The effect of 5-fluorouracil on DNA chain elongation in intact bone marrow cells. Biochem Biophys Res Commun. 1985 Nov 27; 133(1):361-7.
    View PubMed
  212. Diasio RB, Schuetz JD, Wallace HJ, Sommadossi JP. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. Cancer Res. 1985 Oct; 45(10):4900-3.
    View PubMed
  213. Sommadossi JP, Cross DS, Gewirtz DA, Goldman ID, Cano JP, Diasio RB. Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorouracil metabolism with the formation of a glucuronide derivative. Cancer Res. 1985 Jun; 45(6):2450-5.
    View PubMed
  214. Sommadossi JP, Gewirtz DA, Cross DS, Goldman ID, Cano JP, Diasio RB. Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation. Cancer Res. 1985 Jan; 45(1):116-21.
    View PubMed
  215. Mentre F, Steimer JL, Sommadossi JP, Diasio RB, Cano JP. A mathematical model of the kinetics of 5-fluorouracil and its catabolites in freshly isolated rat hepatocytes. Biochem Pharmacol. 1984 Sep 1; 33(17):2727-32.
    View PubMed
  216. Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol. 1984 Apr; 24(4):155-9.
    View PubMed
  217. Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res. 1984 Apr; 44(4):1358-63.
    View PubMed
  218. Kerkering TM, Schwartz PM, Espinel-Ingroff A, Turek PJ, Diasio RB. 5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine. Antimicrob Agents Chemother. 1983 Sep; 24(3):448-9.
    View PubMed
  219. Connolly KM, Diasio RB, Armstrong RD, Kaplan AM. Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine. Cancer Res. 1983 Jun; 43(6):2529-35.
    View PubMed
  220. Diasio RB, Hunter HL, LaBudde JA, Mayol RF, Brouder HP. Pharmacokinetics of ftorafur by parenteral and oral route. Exper and Clin Pharmacother. 1983; 12:31-5.
  221. Diasio RB, Hunter HL, LaBudde JA, Mayol RF, Browder HP. Human pharmacokinetics of parenteral and oral ftorafur (tegafur). Symposium on Ftorafur, Inst. of Organic Synthesis, Latvian Acad. of Sci., Riga, Latvia. 1983.
  222. Connolly KM, Armstrong RD, Diasio RB, Kaplan AM. Host interactions in the effects of 5-fluorouracil on Ehrlich ascites tumor cells. Cancer Res. 1982 Dec; 42(12):4927-35.
    View PubMed
  223. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID. Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem. 1982 Jul 25; 257(14):8171-6.
    View PubMed
  224. Armstrong RD, Diasio RB. Improved measurement of thymidylate synthetase activity by a modified tritium-release assay. J Biochem Biophys Methods. 1982 Jun; 6(2):141-7.
    View PubMed
  225. Armstrong RD, Diasio RB. Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. Cancer Res. 1981 Dec; 41(12 Pt 1):4891-4.
    View PubMed
  226. Hall DJ, Diasio R, Goplerud DR. cis-Platinum in gynecologic cancer. III. Toxicity. Am J Obstet Gynecol. 1981 Oct 1; 141(3):309-12.
    View PubMed
  227. Hall DJ, Diasio R, Goplerud DR. cis-Platinum in gynecologic cancer. II. Squamous cell carcinoma of the cervix. Am J Obstet Gynecol. 1981 Oct 1; 141(3):305-8.
    View PubMed
  228. Hall DJ, Diasio R, Goplerud DR. cis-Platinum in gynecologic cancer. I. Epithelial ovarian cancer. Am J Obstet Gynecol. 1981 Oct 1; 141(3):299-304.
    View PubMed
  229. Diasio RB, Ettinger DS, Satterwhite BE. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. J Clin Pharmacol. 1981 Aug-Sep; 21(8-9 Suppl):81S-85S.
    View PubMed
  230. Diasio RB. Recent advances in cancer chemotherapy. Medical College of Virginia Quarterly. 1981; 16:78-85.
  231. Horsley JS 3rd, Diasio RB. Cancer trends: surgical adjuvant chemotherapy for operable breast cancer. Va Med. 1980 Nov; 107(11):781-4.
    View PubMed
  232. Armstrong RD, Diasio RB. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res. 1980 Sep; 40(9):3333-8.
    View PubMed
  233. Diasio RB. Chemotherapy in the treatment of lung cancer. Cancer News Quarterly. 1980; 1(2).
  234. Bowen D, Diasio RB, Goldman ID. Distinguishing between membrane transport and intracellular metabolism of fluorodeoxyuridine in Ehrlich ascites tumor cells by application of kinetic and high performance liquid chromatographic techniques. J Biol Chem. 1979 Jun 25; 254(12):5333-9.
    View PubMed
  235. Diasio RB, Eanes RZ, Chen ML, Madge GE, Mellette SJ. Adenocarcinoma of the pancreas associated with hypoglycemia: case report and review of the literature. Cancer. 1979 Jun; 43(6):2457-64.
    View PubMed
  236. Diasio RB, Wilburn ME. Effect of column temperature on resolution of fluoropyrimidines by reverse phase high performance liquid chromatography. J Chromatogr Sci. 1979; 17:565-7.
  237. Hall DJ, Kondering KF, Diasio RB, Goplerud DR. Scanning GYN Cancers with CT. Contemp Ob Gyn. 1979; 14:43-56.
  238. Diasio RB, Lakings DE, Bennett JE. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother. 1978 Dec; 14(6):903-8.
    View PubMed
  239. Breiter DN, Diasio RB, Neifeld JP, Roush ML, Rosenberg SA. Serum copper and zinc measurement in patients with osteogenic sarcoma. Cancer. 1978 Aug; 42(2):598-602.
    View PubMed
  240. Diasio RB, Wilburn ME, Shadomy S, Espinel-Ingroff A. Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography. Antimicrob Agents Chemother. 1978 Mar; 13(3):500-4.
    View PubMed
  241. Diasio RB, Bennett JE, Myers CE. Mode of action of 5-fluorocytosine. Biochem Pharmacol. 1978 Mar 1; 27(5):703-7.
    View PubMed
  242. Lakings DB, Adamson RH, Diasio RB. Quantitative analysis of 5-fluorouracil in human serum by selected ion monitoring gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1978; 146:512-7.
  243. Mueller JA, Diasio RB. Genetics and cancer. Medical College of Virginia Quarterly. 1977; 13:154-6.
  244. Myers CE, Diasio R, Eliot HM, Chabner BA. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. Cancer Treat Rev. 1976 Sep; 3(3):175-83.
    View PubMed
  245. Diasio RB, Glass RH. Effects of pH on the migration of X and Y sperm. Fertil Steril. 1971 May; 22(5):303-5.
    View PubMed
  246. Diasio RB, Glass RH. The Y chromosome in sperm of an XYY male. Lancet. 1970 Dec 19; 2(7686):1318-9.
    View PubMed
  247. KERR A Jr, Diasio RB, Bommer WJ. Effect of altitude (hypoxia) on coronary artery size in the white rat. Am Heart J. 1965 Jun; 69:841.
    View PubMed